Stevanato Group (STVN) just posted its third quarter 2026 earnings, reporting sales of €326.1 million and net income of €41.8 million. These results give investors fresh numbers to reassess the stock.
Despite the solid Q3 report and the Aptar Pharma collaboration announced in late October, Stevanato Group's recent trading tells a different story. The share price is down about 30% over the past month and the 1-year total shareholder return has declined about 43%, pointing to fading momentum as investors reassess growth prospects and risk around future syringe volumes.
Compare Stevanato Group's recent pullback with other potential rebound ideas by scanning our hand-picked 35 high quality undervalued stocks that combine quality fundamentals with compressed expectations.
Bulls point to Stevanato Group's growing syringe partnerships and recent margin gains. Bears focus on the sharp share price reset and GLP 1 exposure. Which side does the current valuation support?
Most Popular Narrative: 42% Undervalued
Against a last close of $14.10, the most followed narrative places Stevanato Group's fair value at about $24.47, which implies a wide gap that hinges on execution at its higher value facilities and the mix of premium products.
Scaling commercial production at the Latina and Fishers sites, together with the conversion of an EZ‑fill vial line into an RTU cartridge line and installation of RTU 400 cartridge technology, is intended to meet strong cartridge demand that is already fully covered through 2027 and to reduce current start up dilution, with management guiding to about 170 bps adjusted EBITDA margin expansion in 2026 from mix and ramp effects.
See why 5 investors see Stevanato Group as 42% undervalued .
Result: Fair Value of $24.47 (UNDERVALUED)
Still, there are pressure points in the Stevanato Group story, ranging from rising energy and tax costs to any disappointment in ramping Fishers and Latina to targeted margins.
Find out about the key risks to this Stevanato Group narrative .
Next Steps
Mixed signals around Stevanato Group can either be a red flag or an opening. Move quickly and test the story against the detailed breakdown of 4 key rewards and 1 important warning sign
Looking for more Stevanato Group sized opportunities?
Do not stop your research with Stevanato Group alone. Broaden your watchlist now with focused idea lists that can surface opportunities you might otherwise miss.
-
Target resilient cash generators by reviewing a list of solid balance sheet and fundamentals (23 results) that keeps financial strength front and center when you build your next watchlist.
-
Hunt for mispriced potential and scan a curated 19 high quality undiscovered gems that pairs quality fundamentals with lower investor attention.
-
Prioritize defense and sleep easier at night by filtering for a 30 resilient stocks with low risk scores that screens out fragile balance sheets and unstable earnings profiles.
This article is general in nature and was produced with the assistance of AI automation, based on data and analysis from Simply Wall St. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include STVN .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
